ProCE Banner Activity

Paving the Way to Reduced STIs With Doxycycline PEP in Eastern Europe

Conference Coverage
Clinical Thought

Three studies of doxycycline postexposure prophylaxis for sexually transmitted infections (STIs) were presented at CROI 2024. Here’s how these data potentially affect Central and Eastern Europe, where STI care is less accessible.

Released: March 20, 2024

Share

Faculty

Milosz Parczewski

Milosz Parczewski, MD, PhD

Professor of Medicine
Consultant Physician, ID Specialist
Head
Department of Infectious, Tropical Diseases and Immune Deficiency
Pomeranian Medical University
Szczecin, Poland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

This activity is supported through independent educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Faculty Disclosure

Primary Author

Milosz Parczewski, MD, PhD

Professor of Medicine
Consultant Physician, ID Specialist
Head
Department of Infectious, Tropical Diseases and Immune Deficiency
Pomeranian Medical University
Szczecin, Poland

Milosz Parczewski, MD, PhD: consultant/advisor/speaker: Gilead Sciences, Janssen, Merck Sharp & Dohme, Pfizer, Roche, ViiV/GlaxoSmithKline.